NCT05133245 (PHACE) is a clinical trial of Diagnostic study only in PHACE Syndrome, sponsored by Vanderbilt University Medical Center.

Who is sponsoring NCT05133245?

NCT05133245 is sponsored by Vanderbilt University Medical Center.

What drugs are being tested in NCT05133245?

Interventions in NCT05133245: Diagnostic study only.

What condition does NCT05133245 study?

NCT05133245 studies PHACE Syndrome.

Is NCT05133245 still recruiting?

NCT05133245 is currently enrolling by invitation. Last updated 23 December 2025.

Last reviewed 2025-12-23 · How we verify

NCT05133245: PHACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PHACE - Prospective Genetic Investigation

ENROLLING BY INVITATION Last updated 23 December 2025

What this trial tests

trial testing Diagnostic study only in PHACE Syndrome in 50 participants. Enrolling by invitation.

Timeline

1 November 2021

Primary endpoint
1 November 2026

1 November 2026

Quick facts

Lead sponsor	Vanderbilt University Medical Center
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 November 2021
Primary completion	1 November 2026
Estimated completion	1 November 2026
Sites	1 location across United States

Drugs / interventions tested

Diagnostic study only

Conditions studied

PHACE Syndrome — all drugs for PHACE Syndrome →

Sponsor

Vanderbilt University Medical Center

Who can join

Eligibility, any sex, with PHACE Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigation for potential PHACE syndrome gene.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for PHACE Syndrome

Currently open trials in the same condition.

NCT03440697 — Pathogenetic Basis of Aortopathy and Aortic Valve Disease · active not recruiting

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05133245 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 23 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05133245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing